In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
We recently compiled a list of the 10 Firms Defy Market Pessimism. In this article, we are going to take a look at where Novo ...
As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...
Here are some of the major companies whose stocks moved on the week’s news.
US stocks subdued at open, but S&P 500 inches up to a record high for third straight day. As tariff worries ease for now, ...
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.BqoHa0WQ.js ...
The S&P 500 closed lower after hitting new records on Friday, as investors took some profit to end a solid week centered on President Donald Trump 's return to the White House.
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback